Here's a study confirming the need for more agressive treatment for Type 2 diabetics. Good timing.

http://www.medpagetoday.com/Endocrinology/Diabetes/40698?xid=nl_mpt_DHE_2013-07-27&utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&eun=g499820d0r&userid=499820&email=mskvt@yahoo.com&mu_id=5625514

And another on Lantus not posing a cancer risk.

http://www.medpagetoday.com/Endocrinology/Diabetes/40691?xid=nl_mpt_DHE_2013-07-27&utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&eun=g499820d0r&userid=499820&email=mskvt@yahoo.com&mu_id=5625514

Looks like Afrezza fits in perfecly to become part of best practices in Type 1 and Type 2.